Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels

Circulation Research

Volumn 92, Issue 9, 2003, Pages 969-975

  Wong, Wai man R ^a   Hawe, Emma ^a   Li, Lai K ^a   Miller, George J ^b   Nicaud, Viviane ^c   Pennacchio, Len A ^d   Humphries, Steve E ^a   Talmud, Philippa J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Apolipoprotein AIV; Coronary heart disease risk; Genetic polymorphism; Haplotype analysis

Indexed keywords

APOLIPOPROTEIN A4; TRIACYLGLYCEROL;

ADULT; ALLELE; APOA4 GENE; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE; GENE CLUSTER; GENETIC VARIABILITY; HAPLOTYPE; HAZARD ASSESSMENT; HOMOZYGOSITY; HUMAN; ISCHEMIC HEART DISEASE; MALE; MULTIPLE REGRESSION; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM;

ADOLESCENT; ADULT; ANTIOXIDANTS; APOLIPOPROTEINS A; CORONARY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HAPLOTYPES; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MULTIGENE FAMILY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0038364023     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000069688.94567.7A     Document Type: Article

References (39)

1. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
2. Waterworth DM, Ribalta J, Nicaud V, Dallongeville J, Humphries SE, Talmud P. ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation. 1999;99:1872-1877.
3. Groenendijk M, Cantor RM, de Bruin TW, Dallinga-Thie GM. The apoAI-CIII-AIV gene cluster. Atherosclerosis. 2001;157:1-11.
4. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001; 294:169-173.
5. Pennacchio LA, Olivier M, Hubacek J, Krauss RM, Rubin EM, Cohen JC. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet. 2002;11:3031-3038.
6. Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, Pennacchio LA, Humphries SE. Relative contribution of variation within the APOC3-A4-A5 gene cluster in determining plasma triglycerides. Hum Mol Genet. 2002;11:3039-3046.
7. Shoulders CC, Harry PJ, Lagrost L, White SE, Shah NF, North JD, Gilligan M, Gambert P, Ball MJ. Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma levels of apo CIII. Atherosclerosis. 1991;87:239-247.
8. Bainton D, Miller NE, Bolton CH, Yarnell JW, Sweetnam PM, Baker IA, Lewis B, Elwood PC. Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J. 1992;68:60-66.
9. Shachter NS, Hayek T, Leff T, Smith JD, Rosenberg DW, Walsh A, Ramakrishnan R, Goldberg IJ, Ginsberg HN, Breslow JL. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest. 1994;93:1683-1690.
10. Aalto Setala K, Fisher EA, Chen X, Chajek Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest. 1992;90:1889-1900.
11. Steinmetz A, Utermann G. Activation of lecithin cholesterol acyltransferase by human apolipoprotein A-IV. J Biol Chem. 19852258-2264;.
12. Weinberg RB. Apolipoprotein A-IV polymorphisms and diet-gene interactions. Curr Opin Lipidol. 2002;13:125-134.
13. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol. 1995;6:209-214.
14. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation. 1990;81:470-476.
15. Kronenberg F, Stuhlinger M, Trenkwalder E, Geethanjali FS, Pachinger O, von Eckardstein A, Dieplinger H. Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. J Am Coll Cardiol. 2000;36:751-757.
16. Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost. 1996;75:767-771.
17. Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN, Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet. 2001;358:115-119.
18. Talmud PJ, Hawe E, Robertson K, Miller GJ, Miller NE, Humphries SE. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. Ann Hum Genet. 2002;66:111-124.
19. World Health Organization Regional Office for Europe and Myocardial Infarction Community Register. Public Health in Europe. Copenhagen, Denmark: WHO;5:1976.
20. The EARS group. The European Atherosclerosis Research Study (EARS): design and objectives. Int J Epidemiol. 1994;23:465-471.
21. Rosseneu M, Michiels G, de Keersgieter W, Bury J, De Slypere JP, Dieplinger H, Utermann G. Quantification of human apolipoprotein A-IV by "sandwich"-type enzyme-linked immunosorbent assay. Clin Chem. 1988;34:739-743.
22. Fisher RM, Burke H, Nicaud V, Ehnholm C, Humphries SE, on behalf of the EARS Group. Effect of variation in the apo A-IV gene on body mass index and fasting and postprandial lipids in the European Atherosclerosis Research Study II. J Lipid Res. 1999;40:287-294.
23. Waterworth DM, Talmud PJ, Bujac SR, Fisher RM, Miller GJ, Humphries SE. The contribution of apoCIII gene variants to the determination of triglyceride levels and interaction with smoking in middle-aged men. Arterioscler Thromb Vasc Biol. 2000;20:2663-2669.
24. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001;68:978-989.
25. Tenkanen H, Koskinen P, Metso J, Baumann M, Lukka M, Kauppinen-Makelin R, Kontula K, Taskinen MR, Manttari M, Manninen V. A novel polymorphism of apolipoprotein A-IV is the result of an asparagine to serine substitution at residue 127. Biochim Biophys Acta. 1992;1138:27-33.
26. Bai H, Saku K, Liu R, Oribe Y, Yamamoto K, Arakawa K. Polymorphism of the apolipoprotein A-IV gene and its significance in lipid metabolism and coronary heart disease in a Japanese population. Eur J Clin Invest. 1996;26:1115-1124.
27. Talmud PJ, Humphries SE. Apolipoprotein C-III gene variation and dyslipidaemia. Curr Opin Lipidol. 1997;8:154-158.
28. Olivieri O, Stranieri C, Bassi A, Zaia B, Girelli D, Pizzolo F, Trabetti E, Cheng S, Grow MA, Pignatti PF, Corrocher R. ApoC-III gene polymorphisms and risk of coronary artery disease. J Lipid Res. 2002;43:1450-1457.
29. Warner MM, Guo J, Zhao Y. The relationship between plasma apolipoprotein A-IV levels and coronary heart disease. Chin Med J (Engl). 2001;114:275-279.
30. Duverger N, Tremp G, Caillaud JM, Emmanuel F, Castro G, Fruchart JC, Steinmetz A, Denefle P. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science. 1996;273:966-968.
31. Cohen RD, Castellani LW, Qiao JH, Van Lenten BJ, Lusis AJ, Reue K. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest. 1997;99:1906-1916.
32. Tiret L, Nicaud V, Ehnholm C, Havekes L, Menzel HJ, Ducimetiere P, Cambien F. Inference of the strength of genotype-disease association from studies comparing offspring with and without parental history of disease. Ann Hum Genet. 1993;57:141-149.
33. Zaiou M, Visvikis S, Gueguen R, Parra HJ, Fruchart JC, Siest G. DNA polymorphisms of human apolipoprotein A-IV gene: frequency and effects on lipid, lipoprotein and apolipoprotein levels in a French population. Clin Genet. 1994;46:248-254.
34. Larson IA, Ordovas JM, Sun Z, Barnard, Lohrmann J, Feussner G, Lamon-Fava S, Schaefer EJ. Effects of apolipoprotein A-IV genotype on glucose and plasma lipoprotein levels. Clin Genet. 2002;61:430-436.
35. Vergnes L, Taniguchi T, Omori K, Zakin MM, Ochoa A. The apolipoprotein A-I/C-III/A-IV gene cluster: ApoC-III and ApoA-IV expression is regulated by two common enhancers. Biochim Biophys Acta. 1997;1348:299-310.
36. Qin X, Swertfeger DK, Zheng S, Hui DY, Tso P. Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. Am J Physiol. 1998;274: H1836-H1840.
37. Ostos MA, Conconi M, Vergnes L, Baroukh N, Ribalta J, Girona J, Caillaud JM, Ochoa A, Zakin MM. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:1023-1028.
38. Vergnes L, Baroukh N, Ostos MA, Castro G, Duverger N, Nanjee MN, Najib J, Fruchart JC, Miller NE, Zakin MM, Ochoa A. Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20:2267-2274.
39. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026-2033.